Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11802082 | 0.85 | NR1H2 (0.53) | NR1H2GAATSHRGLAPOLB | |
| SCHEMBL3820235 | 0.84 | GAA (0.50) | NR1H2GAATSHRGLAPOLB | |
| SCHEMBL30789314 | 0.84 | GAA (0.50) | NR1H2GAATSHRGLAPOLB | |
| SCHEMBL8174853 | 0.83 | GAA (0.59) | NR1H2GAATSHRGLAPOLB | |
| SCHEMBL11798096 | 0.82 | NR1H2 (0.50) | NR1H2GAATSHRGLAPOLB | |
| SCHEMBL29889088 | 0.82 | GAA (0.57) | NR1H2GAATSHRGLAPOLB | |
| SCHEMBL545969 | 0.82 | GAA (0.57) | NR1H2GAATSHRGLAPOLB | |
| SCHEMBL2579444 | 0.82 | GAA (0.57) | NR1H2GAATSHRGLAPOLB | |
| SCHEMBL1408378 | 0.80 | PRKCI (0.57) | NR1H2GAATSHRGLAPOLB | |
| SCHEMBL26460616 | 0.80 | GAA (0.55) | NR1H2GAATSHRGLAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024105553-A1 | BICYCLIC HETEROCYCLES AND THEIR USE AS WRN INHIBITORS | NOVARTIS AG (CH) | 2024-05-23 | — | — | WO | disclosed |
| WO-2023009833-A9 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-11-23 | — | — | WO | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10206912-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10206912-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) | 2012-03-01 | — | — | US | disclosed |
| CN-101372475-B | Aromatic heterocyclic substituted diphenyl urea derivative and application thereof | NANJING UNIVERSITY OF TECHNOLOGY | 2012-01-04 | — | — | CN | disclosed |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2011-05-19 | — | — | US | disclosed |
| CN-101671301-A | Heterocyclic substituent acardite derivate and application thereof | JIANGSU PROVINCIAL INST OF MAT | 2010-03-17 | — | — | CN | disclosed |
| CN-101372475-A | Aromatic heterocyclic substituted diphenyl urea derivative and application thereof | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2009-02-25 | — | — | CN | disclosed |
| WO-2008008431-A2 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008431-A2 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-3960890-A | CONTROL OF ECTOPARASITES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | NR1H2 72/4885GAA 4469/4885TSHR 1094/4885 |
| US-10206912-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | NR1H2 72/4885GAA 4469/4885TSHR 1094/4885 |
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 | NR1H2 2147/4885GAA 312/4885TSHR 2117/4885 |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | NR1H2 72/4885GAA 4469/4885TSHR 1094/4885 |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | NR1H2 72/4885GAA 4469/4885TSHR 1094/4885 |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | NR1H2 72/4885GAA 4469/4885TSHR 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.